TABLE 1.
Percentages of capsids immunolabeled with monospecific antiseraa
| Antibody | Virus | % of capsids immunolabeled with antiserum (no. of immunolabeled capsids/no. of capsids examined)
|
|
|---|---|---|---|
| Intact | Sectioned | ||
| ICP35 | HSV-1(F) | 1.8 (18/1007)c | 27.8 (115/413)c |
| pUL6b | HSV-1(F) | 16.3 (53/325)d | 4.0 (48/1181)d |
| pUL6 | UL6− | 0.4 (4/945) | 0.3 (3/929) |
| pUL17b | HSV-1(F) | 13.5 (97/714)d | 5.4 (134/2,447)d |
| pUL17 | UL17− | 0.0 (0/1,000) | 0.2 (2/969) |
| pUL33b | HSV-1(F) | 8.8 (25/281)d | 2.1 (35/1,644)d |
| pUL33 | UL33− | 0.8 (9/1,155) | 0.3 (4/1,042) |
| pUL28b | HSV-1(F) | 8.7 (33/378)e | 4.4 (43/960)e |
| pUL28 | UL28− | 0.7 (8/1,074) | 0.3 (3/973) |
| pUL15Cb | HSV-1(F) | 4.7 (40/847)f | 5.8 (35/595)f |
| pUL15C | UL15− | 1.0 (6/571) | 0.7 (2/1,000) |
Capsids were purified from cells infected with wild-type viruses or viruses lacking the indicated open reading frames (−). In some experiments (intact), capsids were attached to grids and reacted with the indicated antibodies. In other experiments, capsids were embedded and sectioned, followed by reaction of the thin sections with the indicated antibodies. The number of immunolabeled capsids versus the number of capsids examined is indicated in parentheses, and the resulting percentage of labeled capsids is shown. All P values were obtained with Fisher's exact t test.
The amount of immunoreactivity with a given antibody was greater (P < 0.001) in wild-type capsids than in the corresponding deletion mutant capsids.
The immunoreactivity of sectioned capsids was greater than that of intact capsids (P < 0.001).
The immunoreactivity of intact capsids was greater than that of sectioned capsids (P < 0.001).
The immunoreactivty of intact capsids was greater than that of sectioned capsids (P = 0.01).
The immunoreactivity of sectioned capsids compared to that of intact capsids was not statistically different (P = 0.06).